Medical Thromboelastography Machine Market
The market for medical thromboelastography machines was valued at US$ XX billion in 2023 and is projected to reach around US$ XX billion by 2034, expanding at a compound annual growth rate (CAGR) of XX% between 2024 and 2034. Since thromboelastometry aids in the diagnosis, treatment, and monitoring of hemostasis and enhances specific clinical outcomes for patients undergoing heart surgery, the market for medical thromboelastography machines is expanding.
Market Overview
The market for medical thromboelastography machines is expanding quickly because TEG is particularly helpful in large surgeries when blood loss is an issue, such heart surgery. Additionally, it can be used in emergency situations to control bleeding following injury or hemorrhage, monitor coagulation during cardiopulmonary resuscitation, predict bleeding during invasive procedures in patients with cirrhosis and coagulopathy, manage anticoagulation in patients with total heart failure, identify susceptible patients following central venous cannulation in patients with cirrhosis, and identify patients who can undergo minor surgery without risk of bleeding despite strong PT.
Compared to other diagnostic tests, thromboelastography (TEG) has numerous advantages. TEG is becoming a more popular test as proof of its therapeutic effectiveness grows. In patients with hematoma extension and cerebral hemorrhage, TEG can identify coagulation abnormalities. Additionally, TEG can be used to treat hemorrhagic disease, hypertension, severe liver disease, liver disease, and blood loss.
The Impact of Rapid TEG Assays
The development of the rapid diagnostic test (r-TEG) represents a significant advance in diagnosis and improves hemostatic control in the clinic. R-TEG uses tissues to replace the traditional kaolin-cephalin reagent to activate blood coagulation and speed up the diagnostic process by participating in the extrinsic coagulation process. This innovation, which can be tested in 15 minutes, is particularly useful in monitoring blood pressure in trauma patients. In addition, the application of thromboelastometry in cardiac surgery is improving the detection, management, and monitoring of hemostatic conditions, thereby increasing the demand for the medical thromboelastography machine market. The development of diagnostic tools should contribute to economic growth by improving patient outcomes and hospital operations.
Market Trends:
• In April 2024, Haemonetics Corporation, a global healthcare company focused on delivering innovative therapies to improve patient outcomes, announced that its TEG 6s Hemostasis Analysis System has received a 510(k) withdrawal from the U.S. Food and Drug Administration (FDA) Hemostasis-HN test kit. This new box expands the viscoelastic testing capabilities of Haemonetics’ TEG 6 for fully heparinized patients in adult cardiovascular/surgical and liver transplantation in both laboratory and point-of-care settings.
• In July 2022, Werfen’s ROTEM sigma Thromboelastometry System, which enables rapid assessment of critical bleeding at the point of care to reduce inappropriate transfusions and enhanced outcomes, received 510(k) clearance from the U.S. Food and Drug Administration.
• VEM is best studied in surgery and trauma and shows significant promise for use in the emergency department. It has advantages over traditional coagulation tests; it provides information about the entire coagulation cascade and can generally be monitored more rapidly than standard coagulation performed in point-of-care.
• In January 2022, the use of thromboelastography (TEG) in pediatric trauma patients has not been extensively studied. Mortality is higher in patients with TEG-induced coagulopathy. All TEG values were associated with increased mortality when they reached transfusion-trigger cut points.
Enhanced Efficiency and Precision in Thromboelastography Testing Through Automation and AI Integration
The integration of automation and AI into thromboelastography testing offers a significant opportunity to increase the efficiency and accuracy of these diseases. It provides an additional, specific assessment of the severity and various coagulation disorders. TEG technology can be used in many clinical areas, focusing on the point of care, and providing immediate analysis of bone formation and fracture. The development of algorithms that incorporate TEG analysis to manage bleeding patients has been shown to have the potential to reduce blood transfusions and improve clinical outcomes, and the medical thromboelastography machine market for substantial growth as healthcare providers adopt these advanced solutions.
Slower Diagnostics, Higher Costs, Limited Access, and Training Challenges
The growth of the medical thromboelastography machine market is limited by several important factors. The diagnostic process is not as fast as the empirical method, and valuable time can be consumed in critical situations. Furthermore, the overall cost of thromboelastometry can be higher than traditional coagulation tests when accounting for recalibration and maintenance expenses. It is limited to small areas in the region, further restricting access. Furthermore, routine administration of tranexamic acid, which is cost-effective and safe, often requires assessment of fibrinolysis, and special training is required for the quality of its use and interpretation of results. Also, the technology is inadequate in addressing hypothermia-related coagulopathies, further limiting its medical thromboelastography machine market applicability and growth.
Regional Insights
By regional insights North America is dominated in the medical thromboelastography machine market as it is the largest medical market in the world and accounts for more than 40% of the global medical patient technology industry. Medical technology innovators work to provide doctors and other healthcare professionals with the best tools to diagnose and treat patients. This commitment drives more than 6,500 medical technology companies, mostly small and medium-sized enterprises, that produce medical technology every day in the United States. The medical technology industry is a manufacturing success and one of the fastest-growing industries in the United States, that merges rapid innovation with precision product building and distribution. The industry is a world leader, with homegrown R&D, domestic manufacturing in communities large and small, and worldwide exports of American-made products. The advancements in medical technology throughout North America due to the continuous development that has led to the growth of the medical thromboelastography machine market.
Asia Pacific is expected to witness significant growth in the medical thromboelastography machine market during the forecast period as healthcare providers in the region adopt more advanced technologies, including artificial intelligence and cloud technology in their care models. Increasing healthcare spending in the Asia Pacific region is inevitable. Driving the growth of the medical thromboelastography machine market are rising demand for medical devices in the Asia-Pacific region can be ascribed to several factors, including fast-aging populations, growing middle classes, increasing health awareness, and favorable government initiatives.
Segmental Insights
By Type
• By type, single-channel and double-channel segments constitute the medical thromboelastometry machine market as it reduces the risk of sampling and measurement errors. Each chamber has a platform with a disposable cup where the blood sample is collected and a detection pin suspended in its center. The four-channel segment is the fastest growing and it allows experiments with different activators, platelet blockade, and aprotinin or heparinase in addition to four channels at the simultaneous testing time.
By Application
• In terms of application, the hospital segment dominates the medical thromboelastography machine market as it is used to evaluate the hemostatic properties of blood, identify coagulopathies, and guide the management of blood products. Whereas the clinic's segment is fastest growing as the need for organ transplantation and blood loss in heart surgeries, heart transplants, and major trauma.
Recent Developments
• In May 2023, QuidelOrtho and Render organized a New Product Development Conference for IHTEG6 thromboelastography, the newest member of the IHTEG series, at the 20th China Association of Clinical Laboratory Applications (CACLP).
• In March 2024, Haemonetics Corporation Julie Bergeman announced the TEG® 6s hemostasis system uses thromboelastography to provide continuous measurement of clot elasticity.
Top Companies List
• Aemonetics Corporation
• Instrumentation Laboratory
• Framar Hemologix Srl, Medirox AB
• Diagnostica Stago
• Life Diagnostics
• SHINHUA
• Haemonetics, Lepu Technology
• Biomart, Medcaptain,
• Ud-bio Chongqing Nanfang
• WITEYE
• Render
• Guizhou Jinjiu Biotech
• Chongqing Dingrun
• Zhejiang Shengyu
• Bio-zircon
• WerfenLife
• Sienco
Segments Covered:
• By Type
o Single and Double Channel
o Four Channels
o Others
• By Application
o Hospitals
o Clinics
o Blood Banks
o Academic Institutes
• By Geography
o North America
o Europe
o Asia Pacific
o Middle East & Africa
o Latin America
